Literature DB >> 10962353

Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.

S D Neale1, R Smith, J A Wass, N A Athanasou.   

Abstract

A characteristic feature of Paget's disease is an increase in the number of osteoclasts in bone. Osteoclasts are formed from mononuclear phagocyte precursors that circulate in the monocyte fraction of peripheral blood. These cells require the presence of RANK ligand (RANKL)-expressing osteoblastic cells and human macrophage colony-stimulating factor (M-CSF) to form osteoclasts in vitro. To determine the role of osteoclast differentiation from circulating precursors in Paget's disease, we cultured monocytes from Paget's patients and gender- and age-matched normal controls with no evidence of bone disease for up to 21 days in the presence of UMR 106 cells and various concentrations of M-CSF (1-25 ng/mL) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] (10(-10) to 10(-7) mol/L). Relative to controls, there was a significant increase in the extent of osteoclast differentiation from pagetic monocytes as assessed by expression of tartrate-resistant acid phosphatase (TRAP), vitronectin receptor (VNR), and lacunar bone resorption. Serial dilution experiments (2 x 10(5) to 2 x 10(2) cells/well) showed no difference in the concentration of osteoclast precursors in the peripheral blood. In Paget's patients with high serum alkaline phosphatase (sAP) levels, increased sensitivity to the osteoclastogenic effect of 1,25(OH)(2)D(3) was noted. Osteoclast differentiation did not occur when M-CSF was substituted by interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R), and these factors did not stimulate osteoclast differentiation in the presence of M-CSF. In this in vitro coculture system, osteoclast formation was inhibited by osteoprotegerin in a dose-dependent manner. In the presence of RANKL (5-30 ng/mL) and M-CSF (25 ng/mL), osteoclast formation and bone resorption were significantly increased in cultures of monocytes from patients with high and low sAP levels as compared with normal controls. Our findings suggest that the increase in osteoclast numbers seen in Paget's disease results not from an increase in the number of circulating precursors in peripheral blood but rather from an increased sensitivity of osteoclast precursors to the humoral factors, 1,25(OH)(2)D(3) and RANKL, which regulate osteoclast formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962353     DOI: 10.1016/s8756-3282(00)00345-8

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

1.  Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.

Authors:  Noriyoshi Kurihara; Yuko Hiruma; Kei Yamana; Laëtitia Michou; Côme Rousseau; Jean Morissette; Deborah L Galson; Jumpei Teramachi; Hua Zhou; David W Dempster; Jolene J Windle; Jacques P Brown; G David Roodman
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

Review 2.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 3.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

4.  Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.

Authors:  W He; B N Cronstein
Journal:  Purinergic Signal       Date:  2012-02-05       Impact factor: 3.765

Review 5.  Circulating monocytes: an appropriate model for bone-related study.

Authors:  Y Zhou; H-W Deng; H Shen
Journal:  Osteoporos Int       Date:  2015-07-21       Impact factor: 4.507

6.  Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.

Authors:  George Pan; Michael Kilby; Jay M McDonald
Journal:  AIDS Res Hum Retroviruses       Date:  2006-11       Impact factor: 2.205

7.  Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.

Authors:  Jumpei Teramachi; Yuki Nagata; Khalid Mohammad; Yuji Inagaki; Yasuhisa Ohata; Theresa Guise; Laëtitia Michou; Jacques P Brown; Jolene J Windle; Noriyoshi Kurihara; G David Roodman
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

8.  Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease.

Authors:  Noriyoshi Kurihara; Yuko Hiruma; Hua Zhou; Mark A Subler; David W Dempster; Frederick R Singer; Sakamuri V Reddy; Helen E Gruber; Jolene J Windle; G David Roodman
Journal:  J Clin Invest       Date:  2006-12-21       Impact factor: 14.808

9.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

10.  DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells.

Authors:  Kumaran Sundaram; Santhosh K Mani; Kazuyuki Kitatani; Kongming Wu; Richard G Pestell; Sakamuri V Reddy
Journal:  J Cell Biochem       Date:  2008-04-15       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.